No Data
No Data
Trending Industry Today: WUXI BIO Leads Gains In CRO Stocks
PHARMARON: 2024 INTERIM REPORT
HK stocks anomaly | CRO concept stocks continue to rise, hindered by the enactment of the Biosecurity Law, top companies' investment sentiment is expected to marginally improve.
The CRO concept stocks continue to rise. As of the time of publication, Tigermed (03347) rose by 9.28%, to 31.2 Hong Kong dollars; Pharmaron (03759) rose by 4.85%, to 11.24 Hong Kong dollars; and Joinn Laboratories (06127) rose by 4.8%, to 7.64 Hong Kong dollars.
Guosen Securities CXO interim report summary: Integrated leader growth steady, focus on continued recovery of overseas demand.
After experiencing a previous round of adjustments, the current valuation has already fully reflected concerns about future geopolitical uncertainties, with leading revenue and new signings remaining stable. Focus on leading CXOs with a good competitive landscape, efficiency, and cost advantages.
Trending Industry Today: GENSCRIPT BIO Leads Losses In CRO Stocks
The CRO sector is showing strong upward momentum. Pharmaron (03759) rose by 13.48%. Institutions are bullish on the leading domestic clinical CRO company.
Jingu financial news | The CRO sector is strong, with Pharmaron (03759) up 13.48%, WuXi AppTec (02359) up 11.96%, WuXi Biologics (02269) up 11.06%, Tigermed (03347) up 7.14%, Asymchem Laboratories (06821) up 6.92%, Joinn Laboratories (06127) up 5%. Guotai Junan Securities stated that with the US interest rate cut and the continued significant decline in profits of domestic innovative companies, the main reason is the increase in operating expenses. With the support of the pharmaceutical industry, CXO companies' operating performance is expected to gradually bottom out and rebound, and the valuation will
No Data
No Data